Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 4
1996 2
1997 6
1998 3
1999 2
2000 3
2001 1
2004 1
2006 1
2008 3
2009 3
2010 3
2011 3
2013 1
2015 2
2016 1
2017 3
2019 3
2020 1
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
 Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L, Eze C, Taugner J, Nieto A, Hofstetter K, Kröninger S, Guggenberger J, Kenndoff S, Flörsch B, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Käsmann L, et al. Among authors: duell t. J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20. J Cancer Res Clin Oncol. 2023. PMID: 36939927 Free PMC article.
[Follow-Up and Surveillance after Lung Cancer Treatment].
Tufman A, Duell T, Schneider C. Tufman A, et al. Among authors: duell t. Zentralbl Chir. 2019 Feb;144(1):106-117. doi: 10.1055/s-0043-111766. Epub 2019 Feb 19. Zentralbl Chir. 2019. PMID: 30780182 German.
Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.
Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G. Specht HM, et al. Among authors: duell t. Front Immunol. 2015 Apr 15;6:162. doi: 10.3389/fimmu.2015.00162. eCollection 2015. Front Immunol. 2015. PMID: 25926832 Free PMC article. Review.
Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.
Kloker LD, Calukovic B, Benzler K, Golf A, Böhm S, Günther S, Horger M, Haas S, Berchtold S, Beil J, Carter ME, Ganzenmueller T, Singer S, Agaimy A, Stöhr R, Hartmann A, Duell T, Mairhofer S, Fohrer F, Reinmuth N, Zender L, Lauer UM. Kloker LD, et al. Among authors: duell t. Front Oncol. 2022 Oct 27;12:995744. doi: 10.3389/fonc.2022.995744. eCollection 2022. Front Oncol. 2022. PMID: 36387105 Free PMC article.
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J, Käsmann L, Karin M, Eze C, Flörsch B, Guggenberger J, Li M, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Taugner J, et al. Among authors: duell t. Invest New Drugs. 2022 Feb;40(1):163-171. doi: 10.1007/s10637-021-01143-0. Epub 2021 Aug 5. Invest New Drugs. 2022. PMID: 34351518 Free PMC article. Clinical Trial.
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Hofstetter K, et al. Among authors: duell t. Strahlenther Onkol. 2023 Nov 17. doi: 10.1007/s00066-023-02175-6. Online ahead of print. Strahlenther Onkol. 2023. PMID: 37975883
51 results